My Treatment Approach Beyond the First-Line: Expert Insights on Evidence-Driven TKI Selection and Sequencing in Advanced GIST - Episode 4
Post-Imatinib Progression: Decision Factors and Treatment Options
Experts discuss key factors influencing decision-making when patients with advanced gastrointestinal stromal tumors (GIST) progress on imatinib, reviewing standard second-line options, considerations for increasing imatinib dosing vs switching to a different tyrosine kinase inhibitor (TKI), and clinical or radiographic patterns that guide therapy changes or dose escalation at progression.
Video content above is prompted by the following:
- With imatinib as our established first-line therapy for advanced GIST, what key factors influence your decision-making when patients progress? What are our standard second-line options, and what factors influence this treatment selection?
- What specific clinical or molecular factors would lead you to consider increasing imatinib dosing rather than switching to a different TKI?
- What specific clinical or radiographic patterns at the time of progression signal would definitively guide you to switch therapies vs dose escalation?
Related Content:
